Portal Vein Stenting for Jejunal Variceal Bleeding after Recurrence of Pancreatic Adenocarcinoma: A Case Report and Review of the Literature

Seiichiro Takao, Masakazu Hirakawa, Kazuki Takeishi, Yushi Motomura, Katsumi Sakamoto, Hajime Otsu, Yusuke Yonemura, Koshi Mimori, Kousei Ishigami

Abstract

A 73-year-old woman with portal vein stenosis caused by tumor recurrence after pancreatoduodenectomy was treated with stent placement without embolization of the jejunal varix. Anticoagulation therapy using heparin followed by rivaroxaban was administered after the procedure. She continued to receive systemic chemotherapy as an outpatient. Neither restenosis nor stent thrombosis was observed after 7 months. Based on the presented case and literature review, portal vein stenting is an effective treatment option for jejunal variceal bleeding caused by malignant portal venous stricture after pancreatoduodenectomy. Antithrombotic therapy following portal venous stenting is required to prevent stent thrombosis in the majority of cases, although it has a risk of inducing recurrent variceal bleeding. Adjunctive jejunal variceal embolization can possibly be omitted in selected cases to obtain sufficient portal-SMV flow reconstruction.

Key words: Portal vein, Constriction, Stents

Introduction

Recurrent pancreatic cancer can cause portal venous stenosis, resulting in symptoms of portal hypertension, such as hemorrhagic tendencies and liver dysfunction. Pancreatoduodenectomy renders patients susceptible to jejunal varices that often form at the choledochojejunostomy site because the formation of hepatopetal collaterals is precluded after this surgery. Portal vein stenting has been used to treat jejunal variceal hemorrhage. However, no large cohort study to confirm the efficacy of portal venous stenting has yet been reported, and therefore, there is no consensus on the technical details relevant to portal vein stenting, such as the utility of adjunctive embolization of the jejunal varices and anticoagulant/antiplatelet therapy following stenting. This report describes a case of successful stenting for a patient with portal venous stenosis and bleeding from jejunal varices after pancreatoduodenectomy, along with the relevant literature.

Case Presentation

Institutional review board approval was not required at our institution for this type of report.

A 73-year-old Japanese woman suddenly experienced melena and went into hemorrhagic shock (Hb 6.0 g/dL; systemic blood pressure, <60 mmHg). She had undergone subtotal stomach-preserving pancreatoduodenectomy (SSPPD) for pancreatic head adenocarcinoma without portal vein resection 4 years earlier. The final pathological diagnosis was pTNM stage III (pT3N0M0) disease. She had received che-
motherapy for local recurrence and lung metastasis for 2 years.

Computed tomography (CT) on the patient’s admission to our hospital showed portal venous stenosis due to local recurrence, which revealed jejunal varices of the jejunal limb and esophageal and gastric varices (Fig. 1a). Gastrointestinal endoscopy revealed coagula in the remnant stomach and colon, and no obvious bleeding points were detected. These findings suggest that the bleeding was due to a rupture of the jejunal varices caused by extrahepatic portal hypertension, and we thus speculated that portal venous stenting for the emergence of lethal portal hypertension would be beneficial. After considering the case by our hospital’s institutional review board and the patient’s acceptance of portal venous stenting after receiving a thorough explanation of the procedure and its risks, we performed the palliative procedure of a transhepatic insertion of a vascular stent into the portal venous stenosis.

With the patient under local anesthesia, a 6-Fr sheath was inserted at the umbilical portion of the portal vein under sonographic guidance. Portography was performed (Fig. 2a). After the tip of a 0.035-inch guidewire (Radifocus® E type, Terumo, Tokyo, Japan) was shaped manually, we passed through the portal venous stenosis using the upper 0.035-inch wire to insert a catheter (#C2, 4.2 Fr, Medikit, Tokyo, Japan) into the superior mesenteric vein (SMV). Venography showed portal venous stenosis, jejunal varices, and esophageal and gastric varices due to portal hypertension (Fig. 2b, c). The stenosis detected on venography was measured as approximately 5 cm from the portal vein to the splenoportal confluence stenosis. The pressure of the portal vein was 8 mm Hg, but the corresponding pressure of the SMV was 13 mmHg.

The stenotic lesions were dilated with two balloon catheters (Mustang™, 6 × 40 mm and 8 × 40 mm, Boston Scientific, Marlborough, MA, USA); however, the stenoses did not improve. Self-expanding stents (Epic™, 9 × 40 mm and 10 × 50 mm, Boston Scientific, Marlborough, MA, USA) were placed across the stenosis. After stenting, the jejunal varices disappeared quickly (Fig. 2d). Therefore, the jejunal varices were not embolized. The pressure of the SMV decreased from 13 to 8 mmHg, and the pressure gradient between the portal vein and SMV improved. To prevent bleeding from vascular access, the transhepatic parenchymal route was embolized with a gelatin sponge (Spongell®, Astellas Pharma, Tokyo, Japan) through a 6-Fr sheath. We used heparin for anticoagulant therapy with a bolus of 2,000 IU administered at stent insertion followed by continuous infusion at approximately 10,000 IU per day after stenting; 2 days later, the patient was switched to oral administration of rivaroxaban.

The patient was discharged on the 12th postoperative day without any complications. Follow-up CT at 2 months showed portal vein patency (Fig. 1e). The esophageal and gastric varices, as well as jejunal varices, also disappeared despite residual splenic venous stenosis (Fig. 1c). The pa-
Fig. 2. Venography imaging during stent placement. (a) Portography does not show the SMV or SV because of the splenoperaortal confluence stenosis. (b) Superior mesenteric venography shows PV stenosis (arrow) and JVs (curved arrow). (c) Splenic venography shows a gastrorenal shunt and EGVs (asterisk). (d) An expandable-wall stent was placed at the site of PV stenosis (arrowhead). At baseline, the pre- and post-stenotic portal venous pressures were 13 mmHg and 8 mmHg, respectively. After the PV stenting, the pre- and post-stenotic portal venous pressures were both 8 mmHg.

tient received chemotherapy in an outpatient setting. Although the tumor was not controlled, tumor ingrowth or overgrowth has not yet been observed. Eventually, the stent remained patent, and no rebleeding was observed for 7 months after the procedure. The administration of rivaroxaban has been continued to date.

**Literature Review**

We searched for the keywords of "pancreatoduodenectomy" and "portal stent placement" or "portal stenting" in Igaku Chuo Zasshi and PubMed. From 1999 to 2020, there were 26 case reports (Table 1) and 14 research articles, including portal venous stenting after pancreatoduodenectomy (Table 2) [1-40].

The technical success rate was > 99% (failure in one case). The incidence of major complications, such as sepsis, liver abscess, and stent thrombosis, was less than 8% (10 cases). In some cases, bleeding related to the percutaneous transhepatic puncture site occurred, but all recovered conservatively. In most reports, symptoms related to portal hypertension improved without major complications.

In 8 of 18 reports (44.4%), the varices or collateral vessels were embolized at the same time as portal venous stenting. Eight case reports were excluded from this calculation owing to the lack of a statement. In two studies, embolization of collateral vessels was performed in selected cases.

In 15 of the 19 evaluable cases (84.2%), anticoagulation or antiplatelet therapies were administered after stenting. Anticoagulation using warfarin or edoxaban was administered in 8 cases, antiplatelet in 6 cases, and anticoagulation followed by antiplatelet therapy in 1 case. Heparin alone or urokinase was administered to the thrombus in three cases. One patient did not receive any therapy. In seven research articles, anticoagulation or antiplatelet therapies were administered.

**Discussion**

Portal venous stenosis occurs in approximately 12.4% of cases, and symptoms related to portal hypertension that require treatment occur in approximately 1.5%-2.8% of cases after pancreatoduodenectomy [34, 39]. Jejunal varices formed at the site of the choledochojejunostomy are often difficult to detect and treat by gastrointestinal endoscopy [3]. CT can be used to evaluate the anatomic variation of the portal vein [41].

In our case, the stenosis was dilated using a balloon catheter prior to stenting. Pre-dilatation was performed in about half of the cases in our literature review. Although
was achieved after stenting, and there has been no tumor in-
months. This could be because sufficient portal-SMV flow
clusion [33, 36]. However, in our case, variceal embolization
eration did not allow advancement of the stent delivery and
variable related to stent failure [36]. This result suggests that
sufficient expansion of the stent due to the rigid lesion.

There is no consensus regarding the indication, pre-dilatation
should be considered in cases where the stenosis or obstruc-
tion did not allow advancement of the stent delivery and
sufficient expansion of the stent due to the rigid lesion.

Regarding the embolization of collateral veins, Kato et al.
found that the presence of a collateral vein was a significant
variable related to stent failure [36]. This result suggests that
embolization of the collateral veins should be performed for
stent patency. Sakurai et al. also recommended the emboli-
zation of jejunal varices to prevent re-rupture of the varices
during procedure After stenting

Table 1. Cases of portal vein stenting after pancreatoduodenectomy (clinical information)

| No. | Year | Author | Age | Sex | Primary disease | Chief complaint | Postoperative period (months) | Pancytic (Yea) | Improvement of symptoms (Yea No) | Approach Pre-
dilation | Embolization of collateral veins | Antithrombotic therapy | Complication |
|-----|------|--------|-----|-----|----------------|----------------|-----------------------------|--------------|---------------------------------|--------------|-------------------------------|-------------------|-------------|
| 1   | 2001 | Hirota  | 58  | F   | PC Melena, JV  | 12             | 36                          | Yes           | No                              | Yes          | No                            | 1) Heparin         | NS           |
| 2   | 2001 | Hiraoka | 66  | M   | PC Melena, JV  | 27             | 48                          | Yes           | Yes                             | Yes          | No                            | 1) Heparin         | NS           |
| 3   | 2001 | Kozono  | 49  | F   | PC Melena, JV  | 12             | 36                          | Yes           | No                              | Yes          | No                            | 1) Heparin         | NS           |
| 4   | 2002 | Sakai   | 54  | M   | BDC Melena, JV | 20             | 42                          | Yes           | Yes                             | Yes          | No                            | 1) Heparin         | NS           |
| 5   | 2002 | Shimizu | 57  | M   | PC Melena, JV  | 27             | 42                          | Yes           | No                              | Yes          | No                            | 1) Heparin         | NS           |
| 6   | 2002 | Takeuchi| 55  | F   | AC Melena, JV  | 27             | 42                          | Yes           | Yes                             | Yes          | No                            | 1) Heparin         | NS           |
| 7   | 2002 | Yamaura | 67  | M   | PE Melena, JV  | 27 (days)      | 8               | Yes                         | No           | No                            | 4000 IU Heparin    | 24 hours    |
| 8   | 2005 | Sawai   | 64  | M   | CCC Melena, JV | 25             | 14                          | Yes           | Yes                             | Yes No       | No                            | 1) 12000 IU Heparin in 24 hours |
| 9   | 2005 | Sawai   | 64  | M   | PC Melena, JV  | 25             | 14                          | Yes           | No                              | Yes          | No                            | 2) 300 IU Heparin in 6 hours |
| 10  | 2005 | Ellis   | 58  | M   | PC GB Melena, JV | 24             | 36                          | Yes           | Yes                             | Yes No       | No                            | 3) 100 mg day day |
| 11  | 2005 | Kusaka  | 57  | M   | PC Melena, JV  | 24             | 36                          | Yes           | Yes                             | Yes No       | No                            | 4) 5000 IU Heparin in 3 days |
| 12  | 2005 | Takeuchi| 55  | F   | AC Melena, JV  | 27             | 42                          | Yes           | Yes                             | Yes No       | No                            | 5) 100 mg day day |
| 13  | 2005 | Ichihara| 58  | F   | PC Melena, JV  | 27             | 42                          | Yes           | No                              | Yes          | No                            | 6) 12000 IU Heparin in 3 days |
| 14  | 2005 | Shimizu | 57  | M   | AC Melena, JV  | 27             | 42                          | Yes           | No                              | Yes          | No                            | 7) 100 mg day day |
| 15  | 2005 | Sawai   | 64  | M   | CCC Melena, JV | 27             | 42                          | Yes           | No                              | Yes          | No                            | 8) 12000 IU Heparin in 3 days |
| 16  | 2005 | Sawai   | 64  | M   | PC Melena, JV  | 27             | 42                          | Yes           | Yes                             | Yes No       | No                            | 9) 12000 IU Heparin in 3 days |
| 17  | 2005 | Shimizu | 57  | M   | AC Melena, JV  | 27             | 42                          | Yes           | Yes                             | Yes No       | No                            | 10) 12000 IU Heparin in 3 days |
| 18  | 2005 | Shimizu | 57  | M   | PC Melena, JV  | 27             | 42                          | Yes           | Yes                             | Yes No       | No                            | 11) 12000 IU Heparin in 3 days |
| 19  | 2005 | Shimizu | 57  | M   | AC Melena, JV  | 27             | 42                          | Yes           | Yes                             | Yes No       | No                            | 12) 12000 IU Heparin in 3 days |
| 20  | 2005 | Shimizu | 57  | M   | PC Melena, JV  | 27             | 42                          | Yes           | Yes                             | Yes No       | No                            | 13) 12000 IU Heparin in 3 days |
| 21  | 2005 | Shimizu | 57  | M   | PC Melena, JV  | 27             | 42                          | Yes           | Yes                             | Yes No       | No                            | 14) 12000 IU Heparin in 3 days |
| 22  | 2005 | Shimizu | 57  | M   | PC Melena, JV  | 27             | 42                          | Yes           | Yes                             | Yes No       | No                            | 15) 12000 IU Heparin in 3 days |
| 23  | 2005 | Shimizu | 57  | M   | PC Melena, JV  | 27             | 42                          | Yes           | Yes                             | Yes No       | No                            | 16) 12000 IU Heparin in 3 days |
| 24  | 2005 | Shimizu | 57  | M   | PC Melena, JV  | 27             | 42                          | Yes           | Yes                             | Yes No       | No                            | 17) 12000 IU Heparin in 3 days |
| 25  | 2005 | Shimizu | 57  | M   | PC Melena, JV  | 27             | 42                          | Yes           | Yes                             | Yes No       | No                            | 18) 12000 IU Heparin in 3 days |
| 26  | 2005 | Shimizu | 57  | M   | PC Melena, JV  | 27             | 42                          | Yes           | Yes                             | Yes No       | No                            | 19) 12000 IU Heparin in 3 days |

AC: ampullary cancer, BDC: bile duct cancer, CCC: cholangio cellular carcinoma, DC: duodenal cancer, EGV: esophageal varices, GB: gastrointestinal bleeding, HE: hepatic encephalopathy, IPMN: intraductal papillary mucinous neoplasm, iv: intravenous Injection, JV: jejunal varices, LD: liver dysfunction, NS: not stated, PC: pancreatic cancer, PTP: percutaneous transhepatic portal vein approach, TIC: transileocolic vein approach.

There is no consensus regarding the indication, pre-dilatation should be considered in cases where the stenosis or obstruction did not allow advancement of the stent delivery and sufficient expansion of the stent due to the rigid lesion.

Regarding the embolization of collateral veins, Kato et al. found that the presence of a collateral vein was a significant variable related to stent failure [36]. This result suggests that embolization of the collateral veins should be performed for stent patency. Sakurai et al. also recommended the embolization of jejunal varices to prevent re-rupture of the varices due to stent occlusion by tumor growth [15]. After Sakurai's report published in 2014, 6 of 8 evaluable cases (75%) underwent embolization of varices or collateral veins. There have been reports of malignant stenosis or the presence of a collateral vein being associated as a risk factor for stent occlusion [33, 36]. However, in our case, variceal embolization was not performed, stent patency was maintained for 7 months. This could be because sufficient portal-SMV flow was achieved after stenting, and there has been no tumor ingrowth or overgrowth. However, further careful observation is required.

Yamakado et al. reported three factors that were significantly associated with a higher probability of stent occlusion: splenic venous involvement, severe hepatic dysfunction, and portal venous obstruction [42]. This could be explained by a reduction in the portal blood flow after stenting [30]. A recently published study showed that pancreatic fistula was a multivariate derived risk factor [40].

Another factor of stent patency is anticoagulant or antiplatelet therapy [36]. There is controversy regarding therapy after portal venous stenting. Many investigators routinely or selectively use anticoagulant/antiplatelet therapy to prevent stent thrombosis, and heparin is most commonly used during and immediately after stenting. For management with oral medication, the use of antiplatelet and anticoagulant drugs was comparable. It is important to balance anticoagulant therapy with both stent patency and rebleeding from varices. No anticoagulation-related bleeding has been observed in previous studies [40].

Follow-up CT showed an interval decrease in the caliber
DIC: disseminated intravascular coagulation, NS: not stated, PD: pancreaticoduodenectomy, PSP: percutaneous trans-splenic portal vein approach, PTP: percutaneous transhepatic portal vein approach, PV: portal vein, TIC: transileocolic vein approach.

DIC: disseminated intravascular coagulation, NS: not stated, PD: pancreaticoduodenectomy, PSP: percutaneous trans-splenic portal vein approach, PTP: percutaneous transhepatic portal vein approach, PV: portal vein, TIC: transileocolic vein approach.

| No | year | Author | Total case (PD case) | Approach | Pre-dilatation | Embolization of collateral veins | Antithrombotic therapy During procedure | After stenting | Complication (cases) |
|----|------|--------|----------------------|---------|---------------|-------------------------------|----------------------------------------|----------------|---------------------|
| 1  | 1999 | Morita [27] | 8 (1) PTP | Yes | No | 600000 UI of urokinase into the portal vein | 200 mg day<sup>−1</sup> Ticlopidine hydrochloride | Stent thrombosis (1) | DIC (1) |
| 2  | 2005 | Takeshita [28] | 5 (2) PTP | Yes | No | No | No | Intraabdominal bleeding (1) |
| 3  | 2005 | Yamazaki [29] | 4 (4) PTP | Yes | NS | 5000 IU heparin through catheter before stenting | No | No |
| 4  | 2009 | Novellas [30] | 14 PTP | Yes | No | No | No | Liver abscess (1) |
| 5  | 2009 | Woodrum [31] | 18 (6) PTP | No | No | NS | NS | NS |
| 6  | 2009 | Nio [32] | 14 (3) TIC | Yes | NS | NS | 1) 5000 IU day<sup>−1</sup> heparin for a week 2) Aspirin or warfarin for 1–3 months | NS |
| 7  | 2011 | Kim [33] | 19 (9) PTP | Yes | No | No | No | Sepsis (1) Liver abscess (1) Stent thrombosis (1) Hemorrhage related to PV puncture (2) |
| 8  | 2015 | Hiyoshi [34] | 5 (5) PTP | No | No | 2000–3000 IU heparin iv (2 cases) | 1) 500 IU hr<sup>−1</sup> heparin in a day 2) 100 mg day<sup>−1</sup> aspirin for a few years | NS |
| 9  | 2016 | Jeon [35] | 22 (12) PTP | NS | NS | NS | NS | NS |
| 10 | 2017 | Kato [36] | 29 PTP (22) TIC (7) | No | No | No | 1) Heparin for 0–7 days 2) Warfarin for at least 1 year 100 mg aspirin and 75mg clopidogrel for at least 3 months | Stent thrombosis (3) |
| 11 | 2017 | Hyun [37] | 11 (8) PTP (10) PSP (1) | Yes | No | No | No | No |
| 12 | 2017 | Shim [38] | 22 (16) PTP | Yes | 5 cases | 50 IU kg<sup>−1</sup> heparin into the portal vein | No |
| 13 | 2019 | Ohgi [39] | 6 (6) PTP | NS | No | NS | 1) Heparin 2) Warfarin | No |
| 14 | 2020 | Lee [40] | 60 (27) PTP | Yes (not all) 7 cases | 19 cases | 100 mg aspirin and 75mg clopidogrel for at least 3 months | No |

DIC: disseminated intravascular coagulation, NS: not stated, PD: pancreaticoduodenectomy, PSP: percutaneous trans-splenic portal vein approach, PTP: percutaneous transhepatic portal vein approach, PV: portal vein, TIC: transileocolic vein approach.

of the short gastric vein, and the gastroesophageal varices had disappeared (Fig. 1c). In addition, the marginal vein along the transverse colon and middle colic vein were dilated after stenting (Fig. 1b, d). We suspect that the retrograde flow of the splenic vein was altered and drained into the SMV via the marginal vein through the inferior mesenteric vein after stenting (Fig. 3). As a result, the portal blood flow increased, which helped maintain the stent’s patency.

Several studies have reported that pancreaticoduodenectomy with splenic venous transection does not always lead to sinistral portal hypertension, and the preservation of the right colic marginal vein could prevent the development of varices [43, 44]. It is thus speculated that portal venous stenting without preservation of the splenic venous flow is acceptable, as in the present case. However, there is a wide variety of abdominal veins, and the hemodynamic changes due to portal venous stenosis are still unknown.

In conclusion, portal stenting is useful for the management of extrahepatic portal venous stenosis, resulting in portal hypertension and gastrointestinal bleeding. Anticoagulant or antiplatelet therapy following portal venous stenting is required in the majority of cases to prevent acute portal venous stenting, although it has a low risk of inducing recurrent variceal bleeding. Adjunctive jejunal variceal embolization can possibly be omitted in selected cases to obtain sufficient portal-SMV flow reconstruction.
**Fig. 3.** The scheme of blood flow changes before and after stent placement. (a) There were two collateral pathways before stent placement. The first involved the retrograde flow of the splenic vein (SpV), followed by the short gastric vein (SGV). The second involved the retrograde flow of the jejunal vein (JV), which formed JVs and was followed by the peribiliary plexus. (b) The retrograde flow of the SpV and jejunal vein was changed after stent placement. The blood flow of the SpV drained mainly into the SMV via the marginal vein along the transverse colon through the IMV after stent placement. The blood flow of the jejunal vein drained into the SMV, after which the JVs disappeared. IMV: inferior mesenteric vein, JV: jejunal vein, MV: marginal vein, PV: portal vein, SMV: superior mesenteric vein.

**Conflict of Interest:** The authors declare that they have no conflict of interest.

**References**

1. Hiraoka K, Kondo S, Ambo Y, Hirano S, Omi M, Okushima S, Katoh H. Portal venous dilatation and stenting for bleeding jejunal varices: report of two cases. Surg Today 2001; 31: 1008-1011.
2. Koike N, Hatori T, Imaizumi T, Harada N, Fukuda A, Takasaki K. Successful treatment with an expandable metallic stent of gastrointestinal bleeding resulting from anastomotic stricture in the reconstructed region of the portal vein: A case report. Jpn J Gastroneterol Surg 2002; 35: 1394-1398. (in Japanese).
3. Ota S, Suzuki S, Mitsuoka H, et al. Effect of a portal venous stent for gastrointestinal hemorrhage from jejunal varices caused by portal hypertension after pancreateoduodenectomy. J Hepatobil Pancreat Surg 2005; 12: 88-92.
4. Sakai M, Nakao A, Kaneko T, et al. Transelectoral portal venous angioplasty with stenting for bleeding jejunal varices. Hepatogastroenterology 2005; 52: 749-752.
5. Shimizu Y, Yasui K, Furwa N, Arai Y, Yamao K. Late complication in patients undergoing pancreatic resection with intraoperative radiation therapy: gastrointestinal bleeding with occlusion of the portal system. J Gastroenterol Hepatol 2005; 20: 1235-1240.
6. Takeuchi S, Saito H, Hokotate H, Yuasa N, Takei T, Takamura A. A case of rupture of the superior mesenteric varices caused by postoperative portal occlusion: successful treatment with an indwelling metallic stent. Jpn Biliary Association 2006; 20: 50-55. (in Japanese).
7. Yasuda Y, Kato F, Suzuki Y, et al. A case of portal vein stenting for portal vein stenosis after pancreateoduodenectomy. Jpn J Gastroneterol Surg 2006; 39: 1834-1838. (in Japanese).
8. Hwang S, Sung KB, Park YH, Jung DH, Lee SG. Portal vein stenting for portal hypertension caused by local recurrence after pancreateoduodenectomy for peripancreatic cancer. J Gastrointest Surg 2007; 11: 333-337.
9. Ichihara T, Sato T, Miyazawa H, et al. Stent placement is effective on both postoperative hepatic arterial pseudoaneurysm and subsequent portal vein stricture: a case report. World J Gastroenterol 2007; 13: 970-972.
10. Ellis CM, Shenoy S, Litwin A, Soehnlein S, Gibbs JF. Effective endovascular stenting of malignant portal vein obstruction in pancreatic cancer. HPB Surg 2009; 2009: 426436.
11. Koizumi S, Chijiwa K, Ohuchida J, et al. Successful Treatment by Expandable Metallic Stent for gastrointestinal Bleeding from the stenosis of the Portal Vein after Subtotal Stomach preserving pancreateoduodenectomy: report of a Case. Jpn J Gastroneterol Surg 2009; 42: 1711-1716.
12. Hirota M, Yamashita K, Ichihara T. A case of successful treatment with portal stent implantation for gastrointestinal hemorrhage from choledochojejunostomy varices caused by malignant portal vein stenosis after pancreateoduodenectomy. J Abdom. Emerg Med 2010; 42: 1711-1716. (in Japanese).
13. Kubo T, Sakurai J, Ihara H, Tsumura T, Suzuka I. A case of malignant portal vein stenosis after pancreateoduodenectomy, which was successfully treated with stent implantation. J Jpn Surg Assoc 2013; 74: 806-811. (in Japanese).
14. Tsuruga Y, Kamachi H, Wakayama K, et al. Portal vein stenosis after pancreatectomy following neoadjuvant chemoradiation therapy for pancreatic cancer. World J Gastroenterol 2013; 19: 2569-2573.
15. Sakurai K, Amano R, Yamamoto A, et al. Portal vein stenting to treat portal vein stenosis in a patient with malignant tumor and gastrointestinal bleeding. Int Surg 2014; 99: 91-95.
16. Sawatsubashi T, Moriya N, Shimizu T, Nakatsuka H. A Case of Portal Vein stenting for Portal Vein stenosis Due to Pancreatic Cancer Recurrence after pancreateoduodenectomy. Gan To Kagaku Ryoho 2014; 41: 2208-2210. (in Japanese).
17. Wakabayashi M, Kohno S, Hokari T, Aisaki K, Takahashi T,
Takano S. CASE REPORTS OF EXPANDABLE METALLIC STENT TREATMENT FOR gastrointestinal BLEEDING CAUSED BY PORTAL VEIN stenosis after pancreatoduodenectomy. J Jpn Surg Assoc. 2014; 75:2008-2013. (in Japanese).

18. Kitajima T, Fujimoto Y, Hatano E, Taura K, Shibata T, Uemoto S. Portal hypertensive colopathy following percutaneous transhepatic portal venous stenting for benign extrahepatic portal venous stenosis after pancreatoduodenectomy. J Jpn Surg Assoc 2015; 21: 229-237. (in Japanese).

19. Matsui J, Takigawa Y, Kawamata H, et al. Central splenorenal shunt for hemorrhagic varices around a choledochojejunostomy site secondary to extrahepatic portal vein obstruction after pancreatoduodenectomy. Jpn J Gastroenterol Surg 2016; 49: 673-682. (in Japanese).

20. Asai K, Watanabe M, Matsukiyo H, et al. Successful portal vein stent insertion for portal vein stenosis with hemorrhagic varices at the jejunal loop after a pancreatoduodenectomy. J Abdom. Emerg Med 2018; 38: 1059-1064. (in Japanese).

21. Sakabe R, Otsuka H, Tahara H, Hotei H, Maeda Y, Mitogawa Y. Successful treatment with a portal venous stent for gastrointestinal bleeding caused by portal vein stenosis after pancreatoduodenectomy. J Clin Surg 2018; 73: 1293-1298. (in Japanese).

22. Sakamoto T, Arai Y, Morimoto M, et al. Portal vein stenting for portal vein stenosis after pancreatoduodenectomy: A case report. Yonago Acta Med 2018; 61: 182-186.

23. Sawai Y, Kokudo T, Sakamoto Y, et al. Stent placement for benign portal vein stenosis following pancreatoduodenectomy in a hybrid operating room. BioSci Trends 2019; 12: 641-644.

24. Wakisaka Y, Ishido K, Kudo D, Kimura N, Wakiya T, Hakamada K. A case of portal vein stenting for benign portal vein stenosis after subtotal stomach preserved pancreatoduodenectomy. Surgery 2018; 80: 92-98. (in Japanese).

25. Nishihara Y, Seyama Y, Takahashi M, et al. Portal venous stent placement for variceal hemorrhage in the elevated jejunal varices caused by portal vein stenosis after pancreatoduodenectomy: a case report. Nihon Shokakibyo Gakkai Zasshi 2019; 116: 249-255. (in Japanese).

26. Koizumi K, Taniguchi K, Fujita M, et al. A case of portal venous placement for variceal hemorrhage in the elevated jejunal varices caused by portal vein stenosis after pancreatoduodenectomy: a case report. J Natl Def Coll 2020; 45: 37-43. (in Japanese).

27. Morita Y, Hasegawa T, Miyazaki K. The management of collaterals in portal stent implantation. Intervent Radiol 1999; 28: 456-465. (in Japanese).

28. Takeshita A, Fuse A, Hirai I, Kimura W. The significance of placement of a portal stent for portal stenosis. J Jpn Biliary Assoc 2005; 19: 433-439. (in Japanese).

29. Yamazaki S, Kuramoto K, Itoh Y, Watanabe Y, Susa N, Ueda T. Clinical significance of portal venous metal stent placement in recurrent periampullary cancers. Hepato-Gastroenterology 2005; 52: 191-193.

30. Novellas S, Denys A, Bize P, Brunner P, Motamedi JP, Gugenheim J, Caroli FX, Chevallier P. Palliative portal vein stent placement in malignant and symptomatic extrinsic portal vein stenosis or occlusion. Cardiovasc Intervent Radiol 2009; 32: 462-470.

31. Woodrum DA, Bjarnason H, Andrews JC. Portal vein venoplasty and stent placement in the nontransplant population. J Vasc Interv Radiol 2009; 20: 593-599.

32. Nio Y, Iguchi C, Inakura M, et al. Placement of an expandable metallic stent improves the efficacy of chemoradiotherapy for pancreatic cancer with malignant portal vein stenosis or obstruction. Anticancer Res 2009; 29: 3329-3335.

33. Kim KR, Ko CY, Sung KB, et al. Percutaneous transhepatic stent placement in the management of portal venous stenosis after curative surgery for pancreatic and biliary neoplasms. AJR Am J Roentgenol 2011; 196: W446-W450.

34. Hiyoshi M, Fujii Y, Kondo K, et al. Stent placement for portal vein stenosis after pancreatoduodenectomy. World J Surg 2015; 39: 2315-2322.

35. Jeon UB, Kim CW, Kim TU, et al. Therapeutic efficacy and stent patency of transhepatic portal vein stenting after surgery. World J Gastroenterol 2016; 22: 9822-9828.

36. Kato A, Shimizu H, Ohitsuuka M, et al. Portal vein stent placement for the treatment of postoperative portal vein stenosis: long-term success and factor associated with stent failure. BMC Surg 2017; 17: 11.

37. Hyun D, Park KB, Cho SK, et al. Portal vein stenting for delayed jejunal varix bleeding associated with portal venous occlusion after hepatobiliary and pancreatic surgery. Korean J Radiol 2017; 18: 828-834.

38. Shim DJ, Shin JH, Ko CY, et al. Portal vein stent placement with or without varix embolization of jejunal variceal bleeding after hepatoportalbiliary surgery. Acta Radiol 2017; 58: 423-429.

39. Ogih K, Sugiura T, Yamamoto Y, et al. Benign portal vein stenosis after pancreatoduodenectomy. World J Surg 2019; 43: 2623-2630.

40. Lee JH, Yoon CJ, Choi WS, et al. Transhepatic stent placement for portal vein obstruction after hepatobiliary and pancreatic surgery: long-term efficacy and risk factor for stent failure. Eur Radiol 2021; 31: 1300-1307. https://doi.org/10.1007/s00330-020-07139-3.

41. Ishigami K, Sun S, Berst MJ, et al. Portal vein occlusion with aberrant left gastric vein functioning as a hepatopetal collateral pathway. J Vasc Interv Radiol 2004; 15: 501-504.

42. Yamakado K, Nakatsuka A, Tanaka N, Fuji Y, Terada N, Takeda K. Malignant portal venous obstructions treated by stent placement: significant factors affecting patency. J Vasc Interv Radiol 2001; 12: 1407-1415.

43. Hattori M, Fujii T, Yamada S, et al. Significance of the splenic vein and its branches in pancreatoduodenectomy with resection of the portal vein system. Dig Surg 2015; 32: 382-388.

44. Ono Y, Matsueda K, Koga R, et al. Sinistral portal hypertension after pancreatoduodenectomy with splenic vein ligation. Br J Surg 2015; 102: 219-228.